APHINITY trial results to be released by end of March, 2017

Options
stephincanada
stephincanada Member Posts: 228
edited July 2017 in HER2+ (Positive) Breast Cancer

https://www.google.ca/amp/s/www.bloomberg.com/amp/...

TheAPHINITY trial tests the efficacy of pertuzumab (Perjeta) in the adjuvant setting. Fingers crossed for good results!

· Share on FacebookShare on Twitter

Comments

  • argynis
    argynis Member Posts: 123
    edited March 2017

    Today preliminary results (no numbers) were released. Adding Perjeta to adjutant chemotherapy statistically improves disease free survival!

    https://www.gene.com/media/press-releases/14655/2017-03-01/phase-iii-aphinity-study-shows-genentech

    · Share on FacebookShare on Twitter
  • Tara17
    Tara17 Member Posts: 386
    edited March 2017

    does anyone know when numbers will be released ?

    · Share on FacebookShare on Twitter
  • stephincanada
    stephincanada Member Posts: 228
    edited March 2017

    The data are expected to be released at the annual ASCO conference, June 2-6, 2017. However, I don't see it on the preliminary agenda:

    https://am.asco.org/program/preliminary-program

    · Share on FacebookShare on Twitter
  • Tara17
    Tara17 Member Posts: 386
    edited March 2017

    the preliminary agenda won't include any of the new abstracts to be presented I think. Will have to wait for the abstracts to be announced I think

    · Share on FacebookShare on Twitter
  • Tara17
    Tara17 Member Posts: 386
    edited June 2017

    APHIITY got presented at ASCO --although a positive study the results were not as impressive as one had hoped for , based on most of the articles i read discussing the study . Any thoughts ?

    · Share on FacebookShare on Twitter
  • stephincanada
    stephincanada Member Posts: 228
    edited June 2017

    The study confirmed that Herceptin truly is a wonder-drug. It is so effective and does all the heavy lifting; there very little room for Perjeta to improve upon. This is great news for all of the women with HER2 disease who did not take Perjeta. It doesn't seem to add any benefit except in cases of node positive disease, and even there, the benefit is small.

    The editorial on the study by Kathy Miller is an interesting read. Pretty scathing: http://www.nejm.org/doi/full/10.1056/NEJMe1706150#...

    She accuses the investigators of bias; they apparently skewed the numbers to minimize the cardiotoxicity caused by Perjeta. Further, the APHINITY investigators contend that the magnitude of Perjeta's benefit will increase with longer study follow-up time. Miller refutes this argument by saying that anti-HER2 therapies do their work up front, in the short term, and concludes "(i)t seems unlikely that longer follow-up will dramatically change the magnitude of the APHINITY results". Yikes.



    · Share on FacebookShare on Twitter
  • Tara17
    Tara17 Member Posts: 386
    edited June 2017

    steph. Thanks for posting the link to the editorial . Scathing indeed! Anyway its very encouraging for those of us her2 ladies who wont be offered perjeta that its really the herceptin that does all the heavy lifting . So very grateful for herceptin ( and very grateful to all the ladies who participate in these trials !)

    · Share on FacebookShare on Twitter
  • MinusTwo
    MinusTwo Member Posts: 16,634
    edited June 2017

    Yes, thanks for posting Steph. I had neo-adjuvant TCHP, but refused the continuation of Perjeta during the rest of the year with Herceptin - even though I did not have pCR before surgery. I've often questioned whether i did the right thing. This editorial makes me feel more comfortable.

    · Share on FacebookShare on Twitter
  • Tara17
    Tara17 Member Posts: 386
    edited June 2017

    minus two--if you dont mind my asking, what was your reason to refuse perjeta for the rest of the year ? Was it concern about side effects?

    · Share on FacebookShare on Twitter
  • stephincanada
    stephincanada Member Posts: 228
    edited July 2017

    Interesting bit of news re: the APHINITY results.

    https://www.law360.com/articles/931971/roche-faces...

    A number of class actions have been launched against Roche for misleading investors in their March 2/17 press release about Perjeta's benefits.

    I would argue that the press release wasn't just an overstatement of the benefits, it was patently false. The media release claimed that Perjeta benefits people with HER2 disease, when it only benefits a subset of such patients.

    March 2 press release: http://www.roche.com/media/store/releases/med-cor-...

    · Share on FacebookShare on Twitter
  • MinusTwo
    MinusTwo Member Posts: 16,634
    edited July 2017

    Tara - I didn't have pCR with the TCHP. So after surgery I had AC before going back to the Herceptin. By that time I had lost 60 lbs with severe diarrhea. I was a stick figure and was willing to drop anything that might contribute. Also I HOPE that it's that it's true the surgery mopped up any remaining cells, or the AC got them, or the 5 weeks of RADS. As it is, I ended up with breast & truncal lymphadema and permanent CIPN (chemo induced neuropathy) in my numb feet. I'd just had enough.

    I know I took a chance by refusing, since it wasn't offered very often at the time. I suspect it was offered to me because this was a recurrence. My MO supported me either way. I've had 3 clean PET/CTs, as well as MRIs and regular CTs in the last 3-1/2 years. But we all know it's a crap shoot. I will always wonder if I should have continued, but as I said, my poor body couldn't take any more.

    · Share on FacebookShare on Twitter
  • Tara17
    Tara17 Member Posts: 386
    edited July 2017

    Minustwo --thansks for answering why you made the decision you did. I am sorry to hear that you had such a tough time then, glad to hear that you have come a long way since then! It certainly sounds like you made the best decision you possibly could for yourself given all the facts at that time. Now with this new info from APHINITY of minimal clinical benefit, it certainly affirms that you made the right decision !

    · Share on FacebookShare on Twitter

Categories